B. Metzler seel. Sohn & Co. AG Has $1.91 Million Stock Position in BeOne Medicines Ltd. - Sponsored ADR $ONC

Key Points

• B. Metzler seel. Sohn & Co. AG increased its BeOne Medicines position by 73.5% in the second quarter, holding 6,706 shares valued at approximately $1.91 million. Institutional investors collectively own 48.55% of the company.
• BeOne Medicines exceeded quarterly expectations, reporting $2.05 in earnings per share versus the $1.40 consensus and revenue of $1.71 billion against estimates of $1.66 billion.
• Analysts maintain a favorable outlook, with the stock receiving a consensus “Buy” rating and an average price target of $402.14, although insiders sold 588,481 shares worth about $192.9 million over the past three months.

B. Metzler seel. Sohn & Co. AG grew its holdings in shares of BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report) by 73.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 6,706 shares of the company's stock after acquiring an additional 2,840 shares during the period. B. Metzler seel. Sohn & Co. AG's holdings in BeOne Medicines were worth $1,911,000 as of its most recent SEC filing.

A number of other hedge funds also recently modified their holdings of the business. EFG International AG acquired a new position in BeOne Medicines during the 4th quarter worth about $25,000. Leonteq Securities AG acquired a new stake in shares of BeOne Medicines during the fourth quarter worth $35,000. Daiwa Securities Group Inc. bought a new position in BeOne Medicines during the second quarter worth $35,000. CWM LLC raised its stake in BeOne Medicines by 32.8% during the fourth quarter. CWM LLC now owns 158 shares of the company's stock worth $48,000 after buying an additional 39 shares during the last quarter. Finally, Group One Trading LLC acquired a new position in BeOne Medicines in the fourth quarter valued at $61,000. Institutional investors and hedge funds own 48.55% of the company's stock.

BeOne Medicines Stock Performance

Shares of ONC stock opened at $358.26 on Friday. The firm has a market capitalization of $39.33 billion, a PE ratio of 63.07 and a beta of 0.51. The firm has a fifty day simple moving average of $333.94 and a two-hundred day simple moving average of $311.69. The company has a current ratio of 3.40, a quick ratio of 3.06 and a debt-to-equity ratio of 0.17. BeOne Medicines Ltd. - Sponsored ADR has a 12 month low of $253.95 and a 12 month high of $385.22.

BeOne Medicines (NASDAQ:ONC - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported $2.05 earnings per share for the quarter, beating analysts' consensus estimates of $1.40 by $0.65. BeOne Medicines had a net margin of 10.70% and a return on equity of 14.23%. The firm had revenue of $1.71 billion for the quarter, compared to analyst estimates of $1.66 billion. Analysts forecast that BeOne Medicines Ltd. - Sponsored ADR will post 8.81 EPS for the current fiscal year.

Insider Transactions at BeOne Medicines

In other BeOne Medicines news, CEO John Oyler sold 145,861 shares of the business's stock in a transaction that occurred on Tuesday, July 14th. The stock was sold at an average price of $305.95, for a total transaction of $44,626,172.95. Following the completion of the sale, the chief executive officer directly owned 8,122 shares of the company's stock, valued at approximately $2,484,925.90. The trade was a 94.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 588,481 shares of company stock worth $192,918,836. 6.19% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ONC. Barclays upped their price target on shares of BeOne Medicines from $403.00 to $407.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Weiss Ratings reissued a "sell (d-)" rating on shares of BeOne Medicines in a research note on Friday, July 17th. Citizens Jmp upped their target price on BeOne Medicines from $396.00 to $405.00 and gave the company a "market outperform" rating in a research report on Thursday, August 6th. TD Cowen lifted their target price on BeOne Medicines from $424.00 to $454.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Finally, Guggenheim boosted their price target on BeOne Medicines from $420.00 to $430.00 and gave the company a "buy" rating in a research note on Thursday, August 6th. Three equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, BeOne Medicines presently has an average rating of "Buy" and a consensus price target of $402.14.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Want to see what other hedge funds are holding ONC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BeOne Medicines Ltd. - Sponsored ADR (NASDAQ:ONC - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source